Related Experiment Video
Updated: May 28, 2026
07:33
In vitro Organoid Culture of Primary Mouse Colon Tumors
Published on: May 17, 2013
Thyroid transcription factor-1 expression in colorectal adenocarcinomas
Matthias Dettmer1, Tae Eun Kim, Chan Kwon Jung
1Department of Pathology and Laboratory Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
Pathology, Research and Practice
|October 25, 2011
Summary
Thyroid transcription factor-1 (TTF-1) can be expressed in colorectal cancers, but its presence does not correlate with prognosis. TTF-1 should be interpreted alongside other markers like CDX2, CK7, and CK20 for accurate diagnosis.
Area of Science:
- Oncology
- Pathology
- Molecular Biology
Background:
- Thyroid transcription factor-1 (TTF-1) is a common marker for lung and thyroid cancers.
- However, TTF-1 expression can occur in other cancer types, including extrapulmonary adenocarcinomas.
Purpose of the Study:
- To investigate the expression of TTF-1 in colorectal adenocarcinomas.
- To compare TTF-1 staining with other immunohistochemical markers (CK7, CK20, CDX2, MUC2).
- To evaluate the correlation between TTF-1 expression and clinicopathological prognostic factors.
Main Methods:
- Analysis of 555 colorectal adenocarcinoma cases using immunohistochemistry.
- Utilized three commercial monoclonal antibodies for TTF-1 detection (SPT24, 8G7G3/1).
- Assessed expression of cytokeratin (CK) 7, CK 20, caudal-type homeobox transcription factor 2 (CDX2), and MUC2.
Main Results:
- TTF-1 nuclear staining was detected in 4.3% (SPT24) and 3.2% (8G7G3/1) of colorectal adenocarcinomas.
- All TTF-1 positive cases consistently expressed CDX2.
- No significant correlation was found between TTF-1 expression and clinicopathological prognostic factors.
Conclusions:
- TTF-1 expression in colorectal cancer is infrequent and lacks prognostic significance.
- Interpreting TTF-1 in colorectal cancer requires correlation with clinical data, histology, and other markers like CDX2, CK7, and CK20.
- MUC2 may aid in diagnosing challenging cases.
Related Concept Videos
01:30General Transcription Factors
Tissue-specific transcription factors contribute to diverse cellular functions in mammals. For example, the gene for beta globin, a major component of hemoglobin, is present in all cells of the body. However, it is only expressed in red blood cells because the transcription factors that can bind to the promoter sequences of the beta globin gene are only expressed in these cells. Tissue-specific transcription factors also ensure that mutations in these factors may impair only the function of...
02:16Transcription Factors
Tissue-specific transcription factors contribute to diverse cellular functions in mammals. For example, the gene for beta globin, a major component of hemoglobin, is present in all cells of the body. However, it is only expressed in red blood cells because the transcription factors that can bind to the promoter sequences of the beta globin gene are only expressed in these cells. Tissue-specific transcription factors also ensure that mutations in these factors may impair only the function of...
02:16Transcription Factors
Tissue-specific transcription factors contribute to diverse cellular functions in mammals. For example, the gene for beta globin, a major component of hemoglobin, is present in all cells of the body. However, it is only expressed in red blood cells because the transcription factors that can bind to the promoter sequences of the beta globin gene are only expressed in these cells. Tissue-specific transcription factors also ensure that mutations in these factors may impair only the function of...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
02:23Master Transcription Regulators
Master transcription regulators are regulatory proteins that are predominantly responsible for regulating the expression of multiple genes. Often these genes work in concert to drive a complex process. Activation of a master transcription regulator can lead to a cascade of transcriptional activation necessary for that outcome. These regulators can directly bind to the regulatory sequences of the various genes involved, or they can indirectly regulate transcription by binding to regulatory...
01:20Synthesis and Regulation of Thyroid Hormones
Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The iodine is then...
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The iodine is then...